NUWE vs. NEPH, PYPD, LFWD, LUCY, IINN, LYRA, SSKN, CTCX, QTI, and BTCY
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Nephros (NEPH), PolyPid (PYPD), ReWalk Robotics (LFWD), Innovative Eyewear (LUCY), Inspira Technologies Oxy B.H.N. (IINN), Lyra Therapeutics (LYRA), STRATA Skin Sciences (SSKN), Carmell (CTCX), QT Imaging (QTI), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.
Nuwellis vs.
Nephros (NASDAQ:NEPH) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, community ranking, dividends, media sentiment, valuation and earnings.
Nephros has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
In the previous week, Nuwellis had 8 more articles in the media than Nephros. MarketBeat recorded 8 mentions for Nuwellis and 0 mentions for Nephros. Nuwellis' average media sentiment score of 0.91 beat Nephros' score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.
Nuwellis received 9 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 53.66% of users gave Nuwellis an outperform vote while only 43.33% of users gave Nephros an outperform vote.
41.1% of Nephros shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 4.1% of Nephros shares are held by insiders. Comparatively, 2.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nephros currently has a consensus target price of $5.00, indicating a potential upside of 217.66%. Nuwellis has a consensus target price of $17.00, indicating a potential upside of 1,352.99%. Given Nuwellis' stronger consensus rating and higher probable upside, analysts clearly believe Nuwellis is more favorable than Nephros.
Nephros has a net margin of -6.86% compared to Nuwellis' net margin of -169.54%. Nephros' return on equity of -11.39% beat Nuwellis' return on equity.
Nephros has higher revenue and earnings than Nuwellis. Nephros is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Summary
Nephros beats Nuwellis on 10 of the 18 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:NUWE) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NUWE Stock Alerts